AstraZeneca Option Alert: Apr 17 $73 Calls at the Bid: 3000 vs 11 OI; Earnings 4/29 Before Open 

AstraZeneca Option Alert: Apr 17 $73 Calls at the Bid: 3000 @ $1.95 vs 11 OI; Earnings 4/29 Before Open Ref=$73.265

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

biotech shutter

Asia

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

BBIO

BridgeBio&#39;s acoramidis wins Japan&#39;s approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca&#39;s Alexion to market it.

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

Johnson&amp;Johnson.Shutterstock

J&amp;J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study

Jakarta,-,Sept,12,2024:,National,Health,Service,(nhs),England,Signboard

Government

Eurozone

AMGN

BIIB

DSNKY

GILD

RHHBY

UCBJF

UCBJY

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&amp;D investment and falling global competitiveness.

Pharmaceutical Firms Say UK Investment Is &#39;Unlikely&#39; Unless Payment Levy Is Adressed

AstraZeneca PLC - American Depositary Shares

AstraZeneca PLC

Precidian ETFs Trust AstraZeneca PLC ADRhedged

AZN Capital Corp

Press Releases

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer

EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

ATNM

TYO:4568

Axsome Therapeutics

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

TD Cowen

Argus Research

Goldman Sachs

BMO Capital

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

AstraZeneca

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga